PMID- 36947659
OWN - NLM
STAT- MEDLINE
DCOM- 20230526
LR  - 20230526
IS  - 1078-6791 (Print)
IS  - 1078-6791 (Linking)
VI  - 29
IP  - 4
DP  - 2023 May
TI  - Correlation Between Plasma NLRP3, IL-1beta, and IL-18 and Diabetic Nephropathy in 
      Patients With Type 2 Diabetes.
PG  - 52-56
LID - AT8090 [pii]
AB  - CONTEXT: Diabetic nephropathy (DN) is a common microvascular complication in 
      diabetic patients. The pathogenesis of DN is complex. Inflammatory response may 
      play a key role as a common downstream pathway. OBJECTIVE: The study intended to 
      explore the relationship between the levels of plasma nucleotide-binding 
      oligomeric domain-like receptor protein 3 (NLRP3 inflammasome), interleukin-1beta 
      (IL-1beta), and IL-18 and the progression of type 2 diabetic nephropathy to clarify 
      their relationship with type 2 diabetes mellitus (T2DM) and to provide evidence 
      for clinical treatment. DESIGN: The research team performed a controlled 
      observational study. SETTING: The study took place at Baoding No. 1 Central 
      Hospital in Baoding, Hebei, China. PARTICIPANTS: Participants were 153 patients 
      with T2DM who received treatment at the hospital between October 2020 and October 
      2021. The research team allocated 30 participants without evidence of DN to the 
      control group. Based on the DN stage, the team assigned the 123 remaining 
      participants to one of five observation groups: (1) 32 participants with stage 1 
      DN to the DN1 group, (2) 31 participants with stage 2 DN to the DN2 group, (3) 30 
      participants with stage 3 DN to the DN3 group, (4) 30 participants with stage 4 
      DN to the DN4 group, and (5) 29 participants with stage 5 DN to the DN5 group. 
      OUTCOME MEASURES: The research team measured participants' levels of "nucleotide 
      binding oligomeric domain-like receptor protein 3" (NLRP3), interleukin-1 beta 
      (IL-1beta), and IL-18 and used the Spearman rank correlation analysis to determine 
      the correlation between those levels and the DN stages. RESULTS: The levels of 
      NLRP3 , IL-1beta and IL-18 in all the five observation groups were significantly 
      higher than those in the control group (all P < .01). The levels were also 
      significantly higher: (1) in the DN2, DN3, DN4, and DN5 groups than those in the 
      DN1 group (all P < .01); (2) in the DN3, DN4, and DN5 groups than those in the 
      DN2 group (all P < .01); (3) in the DN4 and DN5 groups than those in the DN3 
      group (all P < .01); and (4) in the DN5 groups than those in the DN4 group (all P 
      < .01). The Spearman rank correlation analysis showed that the NLRP3, IL-1beta, and 
      IL-18 levels were significantly positively correlated with the DN stage (P = 
      .01). CONCLUSIONS: NLRP3, IL-1beta and IL-18 played an important role in the 
      progression of T2DM, and their levels increased with the aggravation of DN. 
      Therefore, the plasma levels of NLRP3, IL-1beta and IL-18 can be useful as 
      indicators of the occurrence and development of DN and can provide clinical 
      guidance for the early diagnosis of DN and for the determination and adjustment 
      of treatment plans.
FAU - Yuan, Yangyang
AU  - Yuan Y
FAU - Li, Liqin
AU  - Li L
FAU - Wang, Xiaoyan
AU  - Wang X
FAU - Zhang, Pu
AU  - Zhang P
FAU - Wang, Jun
AU  - Wang J
FAU - Xiao, Yanxin
AU  - Xiao Y
LA  - eng
PT  - Journal Article
PT  - Observational Study
PL  - United States
TA  - Altern Ther Health Med
JT  - Alternative therapies in health and medicine
JID - 9502013
RN  - 0 (Interleukin-18)
RN  - 0 (Interleukin-1beta)
RN  - 0 (NLR Family, Pyrin Domain-Containing 3 Protein)
SB  - IM
MH  - Humans
MH  - *Diabetes Mellitus, Type 2/complications
MH  - *Diabetic Nephropathies/metabolism/pathology
MH  - Interleukin-18/therapeutic use
MH  - Interleukin-1beta/metabolism/therapeutic use
MH  - NLR Family, Pyrin Domain-Containing 3 Protein/analysis/metabolism
EDAT- 2023/03/23 06:00
MHDA- 2023/05/12 07:06
CRDT- 2023/03/22 14:22
PHST- 2023/05/12 07:06 [medline]
PHST- 2023/03/23 06:00 [pubmed]
PHST- 2023/03/22 14:22 [entrez]
AID - AT8090 [pii]
PST - ppublish
SO  - Altern Ther Health Med. 2023 May;29(4):52-56.